Salivary Gland Cancer
42
9
16
14
Key Insights
Highlights
Success Rate
82% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
7.1%
3 terminated out of 42 trials
82.4%
-4.2% vs benchmark
5%
2 trials in Phase 3/4
36%
5 of 14 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 14 completed trials
Clinical Trials (42)
Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer
DESTINY-PANTUMOUR04
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma
APG-115 in Salivary Gland Cancer Trial
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Integrated Cancer Repository for Cancer Research
Amivantamab in Adenoid Cystic Carcinoma
Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas
Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)
Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors
Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers
A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes
Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer
Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
Enhanced Assistance During Radiotherapy for Unmet Essential Needs
A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers
Sacituzumab Govitecan in Metastatic Salivary Gland and Thyroid Cancers (SG-SGTC)
P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)